search
Back to results

Clinical Application of Mg Based Biodegradable Material for Fracture Fixation in the Adult Skeleton

Primary Purpose

Fracture of Medial Malleolus

Status
Completed
Phase
Phase 2
Locations
Austria
Study Type
Interventional
Intervention
BRI.MAG 2
Sponsored by
Medical University of Graz
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Fracture of Medial Malleolus

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients with a dislocated fracture of the medial malleolus. Dislocation is defined as diastasis of the fracture in any direction of 2 mm or more.
  • Otherwise healthy patients (women and men) in the age-group 18 to 65 years
  • Subject has been informed of the nature of the study, agrees to participate and signs the approved consent forms. Included in this procedure is the standard information about the operation procedure.
  • Subject is able and willing to comply with all assessments in the study
  • Female subject with child-bearing potential perform a pregnancy test

Exclusion Criteria:

  • pathological fractures (f.e. bone cyst)
  • underlying diseases (particularly bone diseases, kidney diseases, diabetes mellitus)
  • poly-traumatized patient
  • multiple fractures at the same extremity
  • pregnant or breastfeeding women
  • inability or unwillingness to give informed consent

Sites / Locations

  • Medical University of Graz

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

BRI.MAG 2

Arm Description

Patients presenting with dislocated isolated or combined fracture of the medialis malleolus are eligible to receive the investigational device.

Outcomes

Primary Outcome Measures

Safety: Absence of (Serious) Adverse Events (SAE) throughout the study
(Serious) Adverse Events defined as: Secondary (post-op) diastasis of the distal tibiofibular joint assessed by two plane x-rays Secondary diastasis of the malleolus medialis assessed by two plane x-rays. Infection of the osteosynthesis assessed clinically and/or radiologically with the presence of at least three of the following signs: clinically: pain, swelling, warmth and redness in the infected area, chills and fever x-rays: regional osteopenia, periosteal reaction/thickening, Codman's triangle, focal bony lysis, loss of bony trabecular architecture, new bone apposition
Primary Efficacy- Change of stability of the distal tibiofibular joint
Stability of the distal tibiofibular joint reduced with two BRI.MAG screws assessed by two plane x-rays after surgery, at 2 weeks and at 6 weeks s and at 6 weeks
Primary Efficacy- Change of stability of the fracture of the medial malleolus
Stability of the fracture of the medial malleolus reduced by two BRI.MAG screws assessed by two plane x-rays after surgery, at 2 weeks and at 6 weeks

Secondary Outcome Measures

Procedural success - operation procedure
no change of the operation procedure from conventional to biodegradable
Procedural success- complications
Occurrence of interventional complications (break of material)

Full Information

First Posted
February 2, 2022
Last Updated
January 30, 2023
Sponsor
Medical University of Graz
Collaborators
Laura Bassi Fond; AUVA
search

1. Study Identification

Unique Protocol Identification Number
NCT05245981
Brief Title
Clinical Application of Mg Based Biodegradable Material for Fracture Fixation in the Adult Skeleton
Official Title
Pilot Study: Clinical Application of Mg Based Biodegradable Material for Fracture Fixation in the Adult Skeleton -First in Man Study
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Completed
Study Start Date
July 9, 2018 (Actual)
Primary Completion Date
January 17, 2023 (Actual)
Study Completion Date
January 17, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Medical University of Graz
Collaborators
Laura Bassi Fond; AUVA

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study is a prospective, non-randomized trial for the treatment of fractures of the medial malleolus using lean, bioabsorbable, rare-earth element (REE) free, magnesium (Mg)-based biodegradable screws in the adult skeleton. A total of 20 patients with isolated, bimalleolar, or trimalleolar ankle fractures were recruited between July 2018 and October 2019. Fracture reduction was achieved through bioabsorbable Mg-based screws composed of pure Mg alloyed with zinc (Zn) and calcium (Ca) (0.45 wt% Zn and 0.45 wt% Ca; ZX00). Visual analogue scale (VAS) and the presence of complications (adverse events) during follow-up (12 weeks) were used to evaluate the clinical outcomes. The functional outcomes were analyzed through the range of motion (ROM) of the ankle joint and the American Orthopaedic Foot and Ankle Society (AOFAS) score. Fracture reduction and gas formation were assessed using several plane radiographs.
Detailed Description
The pilot study was designed as a prospective, nonrandomized trial for the treatment of displaced fractures of the medial malleolus with a lean, REE-free, Mg-based biodegradable implant in the adult skeleton. The trial was conducted according to the Good Clinical Practice (ISO 14155:2011) standard and the Declaration of Helsinki.The study was performed at the Department of Orthopaedics and Trauma at the Medical University of Graz and approved by the ethics committee (28 - 071 ex 15/16). A total of 20 subjects were recruited and operated on by three experienced surgeons in the centre between July 2018 and October 2019. Inclusion focused on adults aged between 18 and 65 years presenting with a displaced isolated medial malleolus fracture, a bimalleolar ankle fracture, or a trimalleolar ankle fracture. Fracture displacement was defined as diastasis of the fracture in any direction of 2 mm or more. Exclusion criteria were pathological fractures, underlying diseases (particularly bone diseases, kidney diseases, diabetes mellitus), polytraumatized patients, and pregnant or breastfeeding women.Written informed consent was obtained from each patient before the surgery. All radiological data were stored in a picture archiving and communication system (PACS). Fractures were classified according to the Herscovici system.25 Description of the bioresorbable device used: Ultra-high pure Mg (99.999%) was alloyed with Zn and Ca (0.45 wt% Zn and 0.45 wt% Ca) at 750°C under a protective gas atmosphere. Prepared screws had a length of 40 mm and a diameter of 3.5 mm. Implants were threaded at the distal part for use as traction screws. Surgery: All patients were operated in a supine position. In case of a bimalleolar or trimalleolar fracture, the fibular and the dorsal tibial fragments were treated before the medial malleolus. Subsequently, two parallel Kirschner wires perpendicular to the medial malleolar fracture line were positioned with fluoroscopic control. A cannulated drill bit with 2.7 mm width was used for preparing the hole. Subsequently, one wire was removed and the ZX00 compression screw was inserted into the hole. Final fixation of the fracture was achieved with the second bioabsorbable Mg screw after removal of the second wire. The insertion torque of the screws was limited at a force of 1.5 newton metre with a torque handle. In all patients, no additional implants other than the Mg screws were used for the fixation of the medial malleolus. Patients with bimalleolar fractures and trimalleolar fractures were fixed with titanium plates and screws. Moreover, patients were immobilized with an under-knee plaster cast four to six weeks postoperatively and encouraged to attempt full weight-bearing as tolerated. Ankle movement exercises were started immediately after removal of the plaster. Assessments and measurements: For each subject, the study consisted of assessments conducted preoperatively, immediately after operation and postoperative followup visits. During follow-up, complications including vital signs, erythema, swelling, pain, secretions, wound healing disorders, wound infections, or implant infections were recorded. Pain was assessed using visual analogue scale (VAS). Blood analysis and detection of Ca and Mg were recorded. Functional outcomes were evaluated through range of motion (ROM) in dorsal and plantar flexion. Additionally, the American Orthopaedic Foot and Ankle Society (AOFAS) score was performed after three months. Anteroposterior and lateral ankle radiographs (X-rays) were used to evaluate the fracture union and loss of reduction during follow-up. Postoperative radiograph evaluation was performed by two independent radiologists. The study was registered retrospectively on Clinicaltrials.gov.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Fracture of Medial Malleolus

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
20 (Actual)

8. Arms, Groups, and Interventions

Arm Title
BRI.MAG 2
Arm Type
Experimental
Arm Description
Patients presenting with dislocated isolated or combined fracture of the medialis malleolus are eligible to receive the investigational device.
Intervention Type
Device
Intervention Name(s)
BRI.MAG 2
Intervention Description
Patients presenting with dislocated isolated or combined fracture of the medialis malleolus, will be screened for eligibility. Every effort will be made to ensure eligibility of the patients prior to enrollment. 20 patients will be recruited for the study.
Primary Outcome Measure Information:
Title
Safety: Absence of (Serious) Adverse Events (SAE) throughout the study
Description
(Serious) Adverse Events defined as: Secondary (post-op) diastasis of the distal tibiofibular joint assessed by two plane x-rays Secondary diastasis of the malleolus medialis assessed by two plane x-rays. Infection of the osteosynthesis assessed clinically and/or radiologically with the presence of at least three of the following signs: clinically: pain, swelling, warmth and redness in the infected area, chills and fever x-rays: regional osteopenia, periosteal reaction/thickening, Codman's triangle, focal bony lysis, loss of bony trabecular architecture, new bone apposition
Time Frame
3 years after surgery
Title
Primary Efficacy- Change of stability of the distal tibiofibular joint
Description
Stability of the distal tibiofibular joint reduced with two BRI.MAG screws assessed by two plane x-rays after surgery, at 2 weeks and at 6 weeks s and at 6 weeks
Time Frame
after surgery, at 2 weeks and at 6 weeks
Title
Primary Efficacy- Change of stability of the fracture of the medial malleolus
Description
Stability of the fracture of the medial malleolus reduced by two BRI.MAG screws assessed by two plane x-rays after surgery, at 2 weeks and at 6 weeks
Time Frame
after surgery, at 2 weeks and at 6 weeks
Secondary Outcome Measure Information:
Title
Procedural success - operation procedure
Description
no change of the operation procedure from conventional to biodegradable
Time Frame
6 weeks
Title
Procedural success- complications
Description
Occurrence of interventional complications (break of material)
Time Frame
6 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with a dislocated fracture of the medial malleolus. Dislocation is defined as diastasis of the fracture in any direction of 2 mm or more. Otherwise healthy patients (women and men) in the age-group 18 to 65 years Subject has been informed of the nature of the study, agrees to participate and signs the approved consent forms. Included in this procedure is the standard information about the operation procedure. Subject is able and willing to comply with all assessments in the study Female subject with child-bearing potential perform a pregnancy test Exclusion Criteria: pathological fractures (f.e. bone cyst) underlying diseases (particularly bone diseases, kidney diseases, diabetes mellitus) poly-traumatized patient multiple fractures at the same extremity pregnant or breastfeeding women inability or unwillingness to give informed consent
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Franz Josef Seibert, Prof.Dr.
Organizational Affiliation
Medical University of Graz, Departement of orthopaedics and traumatology
Official's Role
Principal Investigator
Facility Information:
Facility Name
Medical University of Graz
City
Graz
State/Province
Styria
ZIP/Postal Code
8036
Country
Austria

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Clinical Application of Mg Based Biodegradable Material for Fracture Fixation in the Adult Skeleton

We'll reach out to this number within 24 hrs